Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique


Felodipine (FLD), a dihydropyridine calcium channel blocker with excellent antihypertensive effect, is poorly soluble and undergoes extensive hepatic metabolism, which lead to poor oral bioavailability (about 15%) and limit its clinic application. The goal of this study was to develop solid lipid nanoparticles (SLNs) loading FLD to improve the oral bioavailability. The FLD loaded solid lipid nanoparticles (FLD-SLNs) were prepared by the effervescent dispersion technique developed by our laboratory, which might have some advantages over traditional methods. The FLD-SLNs showed desired particle characteristics with particle size (198.15 ± 1.82 nm), poly dispersity index (0.26 ± 0.02), zeta-potential (− 25.53 ± 0.60 mV), entrapment efficiency (95.65 ± 0.70%), drug loading (2.33 ± 0.10%), and a spherical appearance. Pharmacokinetic results showed that the FLD-SLNs presented 3.17-fold increase in area under the curve (AUC(0-t)) compared with free FLD after oral administration in beagle dogs, which indicated that SLNs prepared using the effervescent dispersion technique can improve the bioavailability of lipophilic drugs like felodipine by enhancement of absorption and reduction first-pass metabolism.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. 1.

    Lu Y, Lv Y, Li T. Hybrid drug nanocrystals. Adv Drug Deliv Rev. 2019;143:115–33.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Wu W, Lu Y, Qi J. Editorial: persistent endeavors for the enhancement of dissolution and oral bioavailability. Acta Pharm Sin B. 2019;9(1):2–3.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Huang W, Wu X, Qi J, Zhu Q, Wu W, Lu Y, et al. Ionic liquids: green and tailor-made solvents in drug delivery. Drug Discov Today. 2019;S1359–6446(19):30378–2.

    Google Scholar 

  4. 4.

    Ren X, Qi J, Wu W, Yin Z, Li T, Lu Y. Development of carrier-free nanocrystals of poorly water-soluble drugs by exploring metastable zone of nucleation. Acta Pharm Sin B. 2019;9(1):118–27.

    PubMed  Article  Google Scholar 

  5. 5.

    Liu D, Wan B, Qi J, Dong X, Zhao W, Wu W, et al. Permeation into but not across the cornea: bioimaging of intact nanoemulsions and nanosuspensions using aggregation-caused quenching probes. Chinese Chem Lett. 2018;29(12):1834–183 8.

  6. 6.

    Sahu BP, Das MK. Nanosuspension for enhancement of oral bioavailability of felodipine. Appl Nanosci. 2014;4(2):189–97.

    CAS  Article  Google Scholar 

  7. 7.

    Patel PK. Solid dispersion as a formulation strategy: a mini review. J Chem and Lifesci. 2017;6(6):2039–45.

    Google Scholar 

  8. 8.

    Parashar D, Rajendran V, Shukla R. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. Eur J Pharm Sci. 2019;142:105159.

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Liu C, Liu D, Bai F. In vitro and in vivo studies of lipid-based nanocarriers for oral N3-o-toluyl-fluorouracil delivery. Drug Deliv. 2010;17:352–63.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Rehman A, Tong Q, Jafari SM, Assadpour E, Shehzad Q, Aadil RM, et al. Carotenoid-loaded nanocarriers: a comprehensive review. Adv Colloid Interf Sci. 2019;7:102048.

    Google Scholar 

  11. 11.

    Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–48.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Qi J, Zhuang J, Lu Y, Dong X, Zhao W, Wu W. In vivo fate of lipid-based nanoparticles. Drug Discov Today. 2017;22:166–72.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Hu X, Fan W, Yu Z, Lu Y, Qi J, Zhang J, et al. Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery. Nanoscale. 2016;8(13):7024–35.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Hu X, Zhang J, Yu Z, Xie Y, He H, Qi J, et al. Environment-responsive aza-BODIPY dyes quenching in water as potentialprobes to visualize the in vivo fate of lipid-based nanocarriers. Nanomedicine. 2015;11(8):1939–48.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Gondrala UK, Dudhipala N, Kishan V. Preparation, characterization and in vivo evaluation of felodipine solid-lipid nanoparticles for improved oral bioavailability. Int J Pharm Sci Nanotech. 2015;8(4):2995–3002.

    CAS  Google Scholar 

  16. 16.

    Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 2007;335:167–75.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Chalikwar SS, Belgamwar VS, Talele VR, Surana SJ, Patil MU. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surf B: Biointerfaces. 2012;97:109–16.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Ekambaram P, Abdul HSA. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm. 2011;3(3):216–20.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Parmar B, Mandal S, Petkar KC, Patel LD, Sawant KK. Valsartan loaded solid lipid nanoparticles: development, characterization and in vitro and ex vivo evaluation. Int J Pharm Sci. 2011;1(3):1483–90.

    Google Scholar 

  20. 20.

    Naseri N, Valizadeh H. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5:305–13.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Domb AJ. Lipospheres for controlled delivery of substances. United States Patent. 1993, USS 188837.

  23. 23.

    Zhao L, Ye Y, Li J, Wei Y. Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. J Pharm Pharmacol. 2011;63(1):80–6.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Wei Y, Xue Z, Ye Y, Huang Y, Zhao L. Paclitaxel targeting to lungs by way of liposomes prepared by the effervescent dispersion technique. Arch Pharm Res. 2014;37(6):728–37.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Zhao L, Wei Y, Li W, Liu Y, Wang Y, Zhong X, et al. Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and in vivo evaluation. J Drug Target. 2011;19(3):171–8.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Yuan JY, Pi C, Huang SQ, Liang J, Feng T, Zhan CL, et al. Development and evaluation of felodipine sustained-release tablets. Lat Am J Pharm. 2018;37(1):73–9.

    CAS  Google Scholar 

  27. 27.

    Little WC, Cheng CP, Elvelin L, Nordlander M. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Cardiovasc Drugs Ther. 1995;9(5):657–63.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Li D, Xu S, Wang Y, Li X, Pan J. Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects. Oncotarget. 2017;8(41):70752–60.

    PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Sahu BP, Das MK. Preparation and in vitro/in vivo evaluation of felodipine nanosuspension. Eur J Drug Metab Pharmacokinet. 2014;39(3):183–93.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Navadiya K, Tiwari S. Pharmacology, efficacy and safety of felodipine with a focus on hypertension and angina pectoris. Curr Drug Saf. 2015;10(3):194–201.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Sandeep SM, Sridhar V, Puneeth Y, Babu PR, Babu KN. Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. Drug Dev Ind Pharm. 2014;40(10):1371–7.

    Article  CAS  Google Scholar 

  32. 32.

    Singh M, Kanoujia J, Parashar P, Arya M, Tripathi CB, Sinha VR, et al. Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. Drug Deliv Transl Res. 2018;8(3):1–11.

    Article  CAS  Google Scholar 

  33. 33.

    Rigon RB, Fachinetti N, Severino P, Santana MH, Chorilli M. Skin delivery and in vitro biological evaluation of trans-resveratrol-loaded solid lipid nanoparticles for skin disorder therapies. Molecules. 2016;21(1):E116.

    PubMed  Article  Google Scholar 

  34. 34.

    Yan HM, Zhang ZH, Jiang YR, Ding DM, Sun E, Jia XB. An attempt to stabilize tanshinone IIA solid dispersion by the use of ternary systems with nano-CaCO3 and poloxamer 188. Pharmacogn Mag. 2014;10(Suppl 2):S311–7.

    PubMed  PubMed Central  Google Scholar 

  35. 35.

    Dudhipala N, Veerabrahma K. Improved anti-hyperlipidemic activity of rosuvastatin calcium via lipid nanoparticles: pharmacokinetic and pharmacodynamic evaluation. Eur J Pharm Biopharm. 2017;10:47–57.

    Article  CAS  Google Scholar 

  36. 36.

    Bhalla S, Nagpal M. Comparison of various generations of superporous hydrogels based on chitosan-acrylamide and in vitro drug release. ISRN Pharm. 2013;2013(2):624841.

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Xiao X, Zhu WW, Yuan H, Li WW, Li Q, Yu HQ. Biosynthesis of FeS nanoparticles from contaminant degradation in one single system. Biochem Eng J. 2016;105:214–9.

    CAS  Article  Google Scholar 

  38. 38.

    Wan F, You J, Sun Y, Zhang XG, Cui FD, Du YZ, et al. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm. 2008;359(1–2):104–10.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Ochiuz L, Popa G, Stoleriu I, Tomoiaga AM, Popa M. Microencapsulation of metoprolol tartrate into chitosan for improved oral administration and patient compliance. Ind Eng Chem Res. 2013;52(49):17432–41.

    CAS  Article  Google Scholar 

  40. 40.

    Pathade AD, Kommineni N, Bulbake U. Preparation and comparison of oral bioavailability for different nano-formulations of Olaparib. AAPS PharmSciTech. 2019;20:276.

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Alam T, Pandit J, Vohora D, Aqil M, Ali A, Sultana Y. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv. 2015;12(2):181–94.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Ahmad I, Pandit J, Sultana Y, Mishra AK, Hazari PP, Aqil M. Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: characterization, pharmacokinetic and deposition study. Mater Sci Eng C Mater Biol Appl. 2019;100:959–70.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Soares S, Fonte P, Costa A. Effect of freeze-drying, cryoprotectants and storage conditions on the stability of secondary structure of insulin-loaded solid lipid nanoparticles. Int J Pharm. 2013;456:370–81.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Ong SG, Ming LC, Lee KS, Yuen KH. Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics. 2016;8(3):E25.

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Silki SVR. Enhancement of in vivo efficacy and oral bioavailability of aripiprazole with solid lipid nanoparticles. AAPS Pharm Sci Tech. 2018;9(3):1264–73.

    Article  CAS  Google Scholar 

  46. 46.

    Kai C, Shou LI, Kai J. Formulation optimization of indomethacin-loading solid lipid nanoparticles by box-Behnken response surface methodology. China Pharmacy. 2016;27(22):3118–20.

    Google Scholar 

  47. 47.

    Brubach JB, Jannin V, Mahler B. Structural and thermal characterization of glyceryl behenate by X-ray diffraction coupled to differential calorimetry and infrared spectroscopy. Int J Pharm. 2007;336(2):248–56.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Roberta C, Otto C, Maria EC, Michele T, Carmela S, Maria RG. Sterilization and freeze-drying of drug-free and drug loaded solid lipid nanoparticles. Int J Pharm. 1997;148:47–54.

    Article  Google Scholar 

  49. 49.

    Pi C, Feng T, Liang J, Zhan CL, Wei YM, Zhao. Polymer blends used to develop felodipine-loaded hollow microspheres for improved oral bioavailability. Int J Biol Macromol. 2018;112:1038–47.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Zhao L, Wei Y, Huang Y, He B, Zhou Y, Fu J. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:3769–79.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  51. 51.

    Yang S, Li K. Dissolution profile study on the novel doxycycline hydrochloride sustained-release capsules. Pak J Pharm Sci. 2014;27(5 Suppl):1615–20.

    CAS  PubMed  Google Scholar 

  52. 52.

    Zhang Z, Gao F, Bu H, Xiao J, Li Y. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine. 2012;8(5):740–7.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702–16.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8(11):1407–24.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Reddy RN, Shariff A. Solid lipid nanoparticles: an advanced drug delivery system. Int J Pharm Sci Rev Res. 2013;4:161–71.

    CAS  Article  Google Scholar 

  56. 56.

    Patel RR, Chaurasia S, Khan G, Chaubey P, Kumar N, Mishra B. Highly water-soluble mast cell stabiliser-encapsulated solid lipid nanoparticles with enhanced oral bioavailability. J Microencapsul. 2016;33(3):209–20.

    CAS  PubMed  Article  Google Scholar 

Download references


This study was financially supported by the Science and Technology Fund for Distinguished Young Scholars of Sichuan Province (No.2017JQ0013) and Basic Research (No.2016JY0192), the Joint Fund of Luzhou City and Southwest Medical University (No.2017LZXNYD-T02), the scientific research Foundation of the Education Department of Sichuan Province (No.17ZA0439, 18ZB0646), and the scientific research Foundation of Southwest Medical University (No.2016-63).

Author information



Corresponding authors

Correspondence to Ling Zhao or Yumeng Wei.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest in this work.

Ethical Approval

The animal studies were approved by the Committee on the Ethics of Animal Experiments of the Southwest Medical University (No 2015DW040).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

He, Y., Zhan, C., Pi, C. et al. Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. AAPS PharmSciTech 21, 170 (2020). https://doi.org/10.1208/s12249-020-01711-2

Download citation


  • effervescent dispersion technique
  • felodipine
  • oral bioavailability
  • solid lipid nanoparticles